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Abstract: The limitations of the first-generation everolimus-eluting coronary bioresorbable vascular
scaffolds (BVS) have been demonstrated in several randomized controlled trials. Little data are
available regarding the outcomes of patients receiving hybrid stenting with both BVS and drug-eluting
stents (DES). Of 3144 patients prospectively enrolled in the GABI-Registry, 435 (age 62 ± 10, 19%
females, 970 lesions) received at least one BVS and one metal stent (hybrid group). These patients
were compared with the remaining 2709 (3308 lesions) who received BVS-only. Patients who had
received hybrid stenting had more frequently a history of cardiovascular disease and revascularization
(p < 0.05), had less frequently single-vessel disease (p < 0.0001), and the lesions treated in these patients
were longer (p < 0.0001) and more frequently complex. Accordingly, the incidence of periprocedural
myocardial infarction (p < 0.05) and that of cardiovascular death, target vessel and lesion failure and
any PCI at 24 months was lower in the BVS-only group (all p < 0.05). The 24-months rate of definite
and probable scaffold thrombosis was 2.7% in the hybrid group and 2.8% in the BVS-only group,
that of stent thrombosis in the hybrid group was 1.86%. In multivariable analysis, only implantation
in bifurcation lesions emerged as a predictor of device thrombosis, while the device type was not
associated with this outcome (p = 0.21). The higher incidence of events in patients receiving hybrid
stenting reflects the higher complexity of the lesions in these patients; in patients treated with a hybrid
strategy, the type of device implanted did not influence patients´ outcomes.
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1. Introduction
A number of randomized controlled trials comparing the outcomes of drug eluting stents compared
to first-generation everolimus-eluting coronary bioresorbable vascular scaffolds (BVS) have shown
the limitations of this novel type of devices [1–4]. When compared with drug eluting stents (DES),
the mechanical limitations of BVS, including thicker and wider struts, lower radial strength, and
limited expansion capabilities [5,6] represent important limitations for the treatment of complex lesions,
including ostial or calcific ones, bifurcations, and lesions in small vessels. Supporting this concept,
a number of post-hoc analyses have shown that this type of lesions represents predictors for BVS
failure [7–9] unless a dedicated implantation technique is used [10,11]. Additionally, lesions in the left
main, in by-pass grafts, and restenotic lesions have been excluded from the CE certification from the
very beginning.
Based on these considerations, some authors have advocated for the use of a hybrid approach,
which consists of limiting the use of BVS to settings in which the use of BVS is allowed (or considered
to be safe) [12]. While this strategy is in conflict with the concept of “vascular regeneration” which
represents the foundation of the use of BVS, it might still have the theoretical advantage that vessels
(e.g., the proximal segments) in which long-term complications are clinically more relevant, would
be “stent-free” after device resorption. Independently of the clinical rationale supporting the use of
hybrid stenting, this setting however allows a direct head-to-head comparison of the outcomes of the
device types independently of patients´ characteristics and clinical presentation.
The multicenter German-Austrian ABSORB Registry (GABI-R) was designed to monitor the usage
of BVS in everyday practice. Details on this international registry have been published elsewhere [13].
In the current analysis, we set out to assess the incidence of clinical events in patients receiving hybrid
percutaneous coronary interventions.
2. Methods
Between November 2013 and January 2016, consecutive patients undergoing implantation of
at least one BVS (Absorb; Abbott Vascular, Santa Clara, CA, USA) were enrolled in a prospective
single-arm registry in 92 GABI-R centers. Details on the methods for patients’ inclusion and follow-up
in this observational registry have been previously published [13–15]. The study was conducted in
accordance with the provisions of the Declaration of Helsinki and with the International Conference
on Harmonization Good Clinical Practices, the protocol was approved by each local ethics committee
(first Vote: Ethic committee of the Justus Liebig Universität Giessen 190/13) and all patients provided
written, informed consent. Clinicaltrial.gov NCT02066623
2.1. Objective of the Study
The objective of this study was to investigate the outcome of patients receiving hybrid stenting
with at least one drug eluting stent and one bioresorbable scaffold.
2.2. Procedures
Lesion preparation, BVS implantation, postdilation and use of intracoronary imaging, as well
as medical therapy, were left to the operator’s discretion. The protocol recommended use of pre-
and postdilation. High-pressure dilation was defined as dilation with ≥14ATM. Antiplatelet therapy
consisted of aspirin (loading dose 250–500 mg and maintenance dose 100 mg/day) and clopidogrel
(loading dose at least 300 mg and maintenance dose 75 mg/day), prasugrel (loading dose 60 mg
and maintenance dose 10 mg), or ticagrelor (loading dose 180 mg and maintenance dose 90 mg bid).
Dual antiplatelet therapy was recommended for at least 12 months.
J. Clin. Med. 2019, 8, 767 3 of 13
2.3. Definitions
For the purpose of the present analysis, hybrid stenting was defined as implantation of at least
one Absorb BVS and one metallic stent (BMS or DES) in the same patient. The primary endpoint of the
present study was the incidence of definite/probable device thrombosis in lesions/patients treated with
BVS compared to metallic stents.
Procedural success was defined as visually estimated residual stenosis <30% with thrombolysis
in myocardial infarction flow grade III. Other definitions were based on the Academic Research
Consortium (ARC) criteria [16]. Scaffold thrombosis was defined as definite or probable. Cardiac
death was defined as death from immediate cardiac causes or complications related to the procedure
as well as any death in which a cardiac cause could not be excluded. Myocardial infarction (MI)
was defined according to the World Health Organization extended definition. Target lesion failure
(TLF) was defined as a composite of cardiac death, target vessel MI, and clinically-driven target lesion
revascularization (TLR). Target vessel failure (TVF) was defined as a composite of cardiac death,
target-vessel MI, and clinically driven target vessel revascularization (TVR).
2.4. Data Management and Outcomes of Interest
Data in the GABI-R were collected electronically via an internet-based application and centralized
by the IHF GmbH-Institut für Herzinfarktforschung (Ludwigshafen, Germany). Patients were
contacted by telephone at 30 days, six months and two years using standardized questionnaires.
Follow-up, source verification, quality controls were performed centrally. All events were adjudicated
and classified by an independent event adjudication committee.
2.5. Statistical Analysis
Data are presented as mean± standard deviation, absolute frequencies and percentages, or median
(lower, upper quartile) as appropriate. Data are presented per patient and per lesion. Odds-ratios (95%
confidence limits) are presented to characterize the differences in event frequencies among groups.
The incidence of events in the periprocedural interval and at each of the follow-up times was tested
with Pearson’s Chi-squared test. Concerning device thrombosis, testing for differences on patient level
had to face a highly unbalanced design: There was no reference group for DES/BMS-only treatment.
Thus, we implemented a loglinear model for an incomplete contingency table and three factors: BVS
thrombosis, stent thrombosis, and hybrid treatment, accounting for interactions between the treatment
and device type. To compare times to event (= device thrombosis) and assess the impact of the device
type and hybrid stenting on outcomes, a proportional-hazard model (“Cox regression”) on stent level
was implemented. Intra-subject correlations were considered by using a robust sandwich estimate
aggregating stent residuals to subject level. This multiple regression model included the device type as
a main factor and additional pre-defined predictor variables that have been previously shown to be
associated with scaffold/stent thrombosis in the GABI-R: Total stent length, lesion type, bifurcation
lesion, and time of implantation (before or after January 2015). Missing values were imputed either
by random drawing from the standardized empirical distribution (in case of missing times-to-event),
by modal values (binary) or by median values (metrical variables). A two-tailed p value <0.05 was
considered to indicate statistical significance. Statistical analyses were performed using the SAS®
software, version 9.4 for Windows. Copyright© 2002–2012 SAS Institute Inc. SAS and all other SAS
Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc.,
Cary, NC, USA.
3. Results
3.1. Patient Characteristics
CONSORT flow diagrams are presented in Figure 1 (left and right panel). Of 3144 (4278 lesions)
patients included in the GABI-R registry who received at least one BVS and whose two-years vital
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status was known, 2709 (3308 lesions) were treated with scaffolds only (BVS-only group) while 435
(970 lesions) were treated with at least one additional metallic stent (hybrid group).
Patient characteristics are presented in Table 1. Patients in the hybrid group consistently showed
characteristics compatible with a higher complexity: Glomerular filtration rate was lower (p < 0.05),
the prevalence of prior PCI (p < 0.01), myocardial infarction (p < 0.01), multivessel disease (p < 0.0001),
male sex (p < 0.05) were all higher in the hybrid group and there was a trend towards older age
and higher diabetes prevalence in this group (both = 0.06). In line with this, procedure duration,
contrast use, radiation time, and the number of lesions treated per patient were larger in the hybrid
group (all p < 0.0001). DAPT with prasugrel was used more commonly in the hybrid group (p < 0.05).
The prevalence of smoking was higher in the BVS-only group (p < 0.05).
Table 1. Baseline characteristics of the cohort.
Total (Hybrid + BVS-Only)
n = 3144
Hybrid Group
n = 435
BVS Only
n = 2709 p Value
Female gender 22.9% (721/3144) 19.1% (83/435) 23.6% (638/2709) <0.05
Age (years, rounded) 60.87 ± 11.02 61.91 ± 10.36, 60.7 ± 11.11 0.06
Diabetes mellitus 20.9% (651/3117) 24.2% (105/433) 20.3% (546/2684) 0.06
Current smoker 34.9% (1039/2978) 30.4% (128/421) 35.6 % (911/2557) <0.05
Arterial hypertension 73.4% (2274/3100) 75.3% (324/430) 73% (1950/2670) 0.31
Hypercholesterolemia 56.5% (1702/3010) 59.6% (243/408) 56.1% (1459/2602) 0.19
Glomerular filtration rate 79.39 ± 23.68, n = 1590 75.33 ± 22.55, n = 165 79.86 ± 23.77, n = 1425 <0.05
History of myocardial
infarction 22.2% (687/3094) 27.4% (117/427) 21.4% (570/2667) <0.01
History of PCI 33.9% (1044/3079) 39.6% (169/427) 33% (875/2652) <0.01
History of aorto-coronary
bypass surgery 2.5% (79/3131) 3% (13/433) 2.4% (66/2698) 0.49
History of CAD 41.1% (1137/2768) 44% (178/405) 40.6% (959/2363) 0.20
History of stroke 2.7% (85/3143) 3% (13/435) 2.7% (72/2708) 0.69
Acute coronary syndrome at
presentation 51.4% (1617/3143) 47.8% (208/435) 52% (1409/2708) 0.10
Stable angina pectoris 33.5% (1053/3143) 33.1% (144/435) 33.6% (909/2708) 0.85
Left ventricular ejection
fraction 56.09 ± 10.5, n = 1930 54.84 ± 10.15, n = 282 56.31 ± 10.55, n = 1648 <0.05
1-vessel CAD 41.9% (1317/3144) 20% (87/435) 45.4% (1230/2709) <0.0001
2-vessels CAD 31% (974/3144) 35.6% (155/435) 30.2% (819/2709) <0.05
3-vessel CAD 27.1% (852/3144) 44.4% (193/435) 24.3% (659/2709) <0.0001
Values are mean ± SD or % (absolute number/number of available records); CAD = coronary artery disease; PCI =
percutaneous coronary intervention, CBR = clinical BVS restenosis.J. Clin. Med. 2019, 8, x 5 of 15 
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The large majority of metallic stents were DES (total of DES used: 610), and only three BMS were
used. Interventions in the hybrid group were more frequent in the LAD, those in the BVS-only group
were more frequent in the RCA (p < 0.0001 and p < 0.05). Compatible with the above differences
between groups, all parameters expressing lesion complexity were more frequent in the hybrid group:
The prevalence of B2 (p < 0.05), C1 (p < 0.0001), C2 (p < 0.05) lesions, bifurcation lesions (p < 0.0001),
chronic total occlusions (p < 0.0001), lesions with severe tortuosity (p < 0.05), presence of calcium
(p < 0.05), and lesion length (p < 0.0001) were higher in the hybrid group than in the BVS only group.
Predilatation was performed in 93.5% of BVS-only treated patients and 85.7% of patients treated with
hybrid-PCI (p < 0.0001). The use of high-pressure inflations, scoring balloons, rotablator, was more
frequent in the hybrid group (p < 0.001). In contrast, postdilation was performed more frequently
(73.6% compared to 68.4% in BVS-only patients.
Table 2. Angiographic and procedural characteristics.
Total (Hybrid + BVS-Only) Hybrid Group BVS Only p Value
Procedure duration, minutes 58.90 ± 28.91, n = 3141 77.83 ± 35.96, n = 435 55.85 ± 26.38, n = 2706 <0.0001
Radiation time, minutes 11.84 ± 8.22, n = 3143 18.05 ± 10.64, n = 435 10.84 ± 7.28, n = 2708 <0.0001
Amount of contrast medium,
mL 174.76 ± 74.65, n = 3140 223.40 ± 91.21, n = 435 166.94 ± 68.50, n = 2705 <0.0001
IVUS 3% (94/3142) 2.8% (12/435) 3% (82/2707) 0.76
OCT 4.5% (141/3142) 4.6% (20/435) 4.5% (121/2707) 0.90
Per lesion
Treated segments 4278 970 3308
Lesions treated with BRS only 87.3% (3670/4204) 43.8% (417/951) 100% (3253/3253)
Lesions treated with stents
only 9.8% (410/4204) 43.1% (410/951) 0% (0/3253)
Intervention in LAD 74.7% (1582/2118) 84.7% (287/339) 72.8% (1295/1779) <0.0001
Intervention in LCX 59.6% (813/1363) 63.8% (153/240) 58.8% (660/1123) 0.15
Intervention in RCA 68.4% (1051/1537) 62.8% (155/247) 69.5% (896/1290) <0.05
Graft 23.8% (5/21) 0% (0/1) 25% (5/20) 0.57
Lesion type
A 26.5% (1133/4270) 19.4% (187/964) 28.6% (946/3306) <0.0001
B1 37% (1579/4270) 36.1% (348/964) 37.2% (1231/3306) 0.52
B2 19.6% (836/4270) 21.9% (211/964) 18.9% (625/3306) <0.05
C1 12.6% (539/4270) 17% (164/964) 11.3% (375/3306) <0.0001
C2 4.3% (183/4270) 5.6% (54/964) 3.9% (129/3306) <0.05
De novo lesion 94.2% (4025/4272) 92.9% (897/966) 94.6% (3128/3306) <0.05
Ostial lesion 0.8% (36/4272) 0.5% (5/966) 0.9% (31/3306) 0.21
Bifurcation lesion 2.9% (123/4272) 5.5% (53/966) 2.1% (70/3306) <0.0001
100% stenosis 5.6% (241/4272) 5.7% (55/966) 5.6% (186/3306) 0.94
Chronic total occlusion 37.3% (90/241) 63.6% (35/55) 29.6% (55/186) <0.0001
Severe tortuosity 1.2% (52/4263) 1.9% (18/961) 1% (34/3302) <0.05
No calcification 35.9% (1533/4270) 33.2% (320/964) 36.7% (1213/3306) <0.05
% Stenosis 86.30 ± 11.73, n = 4275 84.92 ± 11.93, n = 968 86.71 ± 11.65, n = 3307 <0.0001
Imaging 3.2% (136/4275) 1.8% (17/968) 3.6% (119/3307) <0.01
FFR 5.2% (223/4262) 6.7% (64/961) 4.8% (159/3301) <0.05
RVD 2.95 ± 0.63, n = 93 3.15 ± 0.43, n = 11 2.92 ± 0.64, n = 82 0.26
Lesion length 17.12 ± 9.30, n = 4258 18.84 ± 10.51, n = 956 16.62 ± 8.85, n = 3302 <0.0001
Lesion length >34 mm 5.6% (238/4258) 8.4% (80/956) 4.8% (158/3302) <0.0001
Any lesion preparation 91.7% (3921/4274) 85.7% (830/968) 93.5% (3091/3306) <0.0001
Pre-dilatation 100% (3920/3921) 100% (830/830) 100% (3090/3091) 0.60
High pressure balloon 43% (1680/3908) 49.3% (408/828) 41.3% (1272/3080) <0.0001
Non-compliant balloon 73% (1215/1665) 85.3% (348/408) 69% (867/1257) <0.0001
Use of scoring balloon 3% (116/3921) 5.4% (45/830) 2.3% (71/3091) <0.0001
Rotablation 0.2% (6/3921) 0.6% (5/830) 0% (1/3091) <0.001
Stent/BVS size, mm 3.07 ± 0.59, n = 4960 3.03 ± 0.45, n = 1243 3.08 ± 0.63, n = 3717 <0.001
Postdilatation performed 72.4% (3093/4271) 68.4% (660/965) 73.6% (2433/3306) <0.01
High-pressure Postdilation 89.5% (2766/3090) 86.9% (573/659) 90.2% (2193/2431) <0.05
PSP-technique 6.4% (244/3794) 12.6% (68/541) 5.4% (176/3253) <0.0001
Procedural success 99% (4229/4273) 98.7% (954/967) 99.1% (3275/3306) 0.27
Glycoprotein IIb/IIIa inhibitors 8% (252/3143) 6.7% (29/435) 8.2% (223/2708) 0.26
Medical therapy at discharge
Aspirin 97.3% (3056/3141) 95.9% (417/435) 97.5% (2639/2706) <0.05
P2Y12-receptor
inhibitorsClopidogrel 44% (1351/3068) 41.2% (175/425) 44.5% (1176/2643) 0.2
Prasugrel 34.1% (1045/3068) 38.6% (164/425) 33.3% (881/2643) <0.05
Ticagrelor 21.9% (672/3068) 20.2% (86/425) 22.2% (586/2643) 0.37
Values are mean ± SD, median (quartiles) or % (absolute number/number of available records); BVS = bioresorbable
vascular scaffold; CBR = clinical BVS restenosis; DES = drug eluting stent; PCI = percutaneous coronary intervention.
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Lesion and procedural characteristics in the hybrid group are presented in Table 3. Of the
970 lesions in patients in the hybrid group, 417 (43.8%) had been treated with BVS only, 410 (43.1%)
with DES/BMS only and there was a total of 124 lesions treated with overlapping hybrid strategy
(2.9% of the total, 12.8% of the lesions treated in patients who received hybrid revascularization).
An additional 19 were not classified in the database. When lesions treated with BVS-only were
compared to lesions treated with DES/BMS only, BVS-only lesions were longer, more frequently type
C2 (both p < 0.05), and there was a trend towards more frequent chronic total occlusions (p = 0.06).
Only the prevalence of bifurcation lesions was higher in the DES/BMS-treated lesions (p < 0.0001).
There was a total of 25 Medina 1,1,1 lesions, and 2 Medina 0,1,1 lesions in the hybrid group. There were
only three cases of hybrid bifurcation stenting (metallic stent + BVS in the same bifurcation lesion).
In terms of procedural parameters, larger predilation balloons, imaging and postdilation were used
more frequently in BVS-treated lesions (p < 0.01, p < 0.05 and p < 0.0001). Procedural success was 99%
in both groups.
Table 3. Lesion-level analysis, bioresorbable vascular scaffold (BVS)-treated lesions compared to lesions
treated with metallic stents in the hybrid group.
Total BVS Only DES/BMS StentOnly p Value OR (95%-CI)
Number of lesions 827 417 410
Stenosis (%) before PCI 84.42 ± 11.94,n = 827
84.47 ± 11.36,
n = 417
84.37 ± 12.51,
n = 410 0.69
RVD (mm) 2.96 ± 0.29,n = 6
2.96 ± 0.24,
n = 3
2.95 ± 0.39,
n = 3 1
Lesion length (mm) 18.01 ± 9.9, n = 815 18.6 ± 9.66, n = 411 17.41 ± 10.1, n = 404 <0.05
Lesion length >34 mm 6.5 % (53/815) 6.8% (28/411) 6.2% (25/404) 0.72 1.11(0.63–1.94)
Morphology
A 20.4% (168/823) 21.4% (89/416) 19.4% (79/407) 0.48 1.13(0.80–1.59)
B1 36.2% (298/823) 36.8% (153/416) 35.6% (145/407) 0.73 1.05(0.79–1.40)
B2 22.6% (186/823) 20% (83/416) 25.3% (103/407) 0.07 0.74(0.53–1.02)
C1 15.6% (128/823) 15.1% (63/416) 16% (65/407) 0.74 0.94(0.64–1.37)
C2 5.2% (43/823) 6.7% (28/416) 3.7% (15/407) <0.05 1.89(0.99–3.59)
De novo vessel 93% (767/825) 93.8% (391/417) 92.2% (376/408) 0.37 1.28(0.75–2.19)
In-stent re-stenosis 1% (8/825) 0.5 % (2/417) 1.5% (6/408) 0.15 0.32(0.06–1.61)
Bifurcation 5.9% (49/825) 2.4% (10/417) 9.6% (39/408) <0.0001 0.23(0.11–0.47)
Complete occlusion 5.3% (44/825) 6.2% (26/417) 4.4% (18/408) 0.24 1.44(0.78–2.67)
CTO 61.4% (27/44) 73.1% (19/26) 44.4% (8/18) 0.06 3.39(0.95–12.09)
Ostial lesion 0.6% (5/825) 0.2% (1/417) 1% (4/408) 0.17 0.24(0.03–2.18)
Severe tortuosity 2% (16/820) 1.2% (5/416) 2.7% (11/404) 0.12 0.43(0.15–1.26)
No calcification 33.7% (277/823) 36.3% (151/416) 31% (126/407) 0.11 1.27(0.95–1.7)
Mild 43.7% (360/823) 44.2% (184/416) 43.2% (176/407) 0.78 1.04(0.79–1.37)
Moderate 18.2% (150/823) 15.9% (66/416) 20.6% (84/407) 0.08 0.73(0.51–1.04)
Severe 4.4% (36/823) 3.6% (15/416) 5.2% (21/407) 0.28 0.69(0.35–1.35)
J. Clin. Med. 2019, 8, 767 7 of 13
Table 3. Cont.
Total BVS Only DES/BMS StentOnly p Value OR (95%-CI)
Procedural Characteristics
Pre-dilatation 100% (693/693) 100% (396/396) 100% (297/297) n.d.
High pressure balloon 51.1% (353/691) 52.3% (207/396) 49.5% (146/295) 0.47 1.12(0.83–1.51)
Maximum balloon
diameter (mm) 2.75 ± 0.46, n = 689 2.79 ± 0.41, n = 395 2.69 ± 0.5, n = 294 <0.01
Scoring balloon 5.8% (40/693) 6.8% (27/396) 4.4 % (13/297) 0.17 1.6(0.81–3.15)
Rotablation 0.6% (4/693) 0.5% (2/396) 0.7% (2/297) 0.77 0.75(0.10–5.35)
Post-dilatation 66.8% (551/825) 85.5% (355/415) 47.8% (196/410) <0.0001
High pressure balloon 86.5% (476/550) 89.9% (319/355) 80.5% (157/195) <0.01
Intravasc. imaging
(IVUS/OCT/QCA) after
PCI
1.6% (13/827) 2.6% (11/417) 0.5% (2/410) <0.05
Procedural success 99% (819/827) 99% (413/417) 99% (406/410) 0.98
Values are mean ± SD or % (absolute number/number of available records).
3.2. Clinical Outcomes
The incidence of periprocedural myocardial infarction (p < 0.05, OR 4.2(1.2–14.9)) and vessel
perforation (p < 0.001, OR 4.9(1.8–13.2)) was higher in the hybrid group. Otherwise, there was no
difference in the incidence of periprocedural events.
At 30 days (Table 4), the incidence of cardiovascular death, target vessel and target lesion failure
were higher in the hybrid group. Similarly, at 24-month follow-up (follow up available in 98.4% of the
patients), the incidence of cardiovascular death (p < 0.05, OR 2.3(1.0–5.2)), target vessel failure (p < 0.01,
OR 1.7(1.2–2.3)) and target lesion failure (p < 0.05, OR 1.6(1.1–2.3)), and that of any PCI (p < 0.05, OR
1.4(1.1–1.8)), were higher in the hybrid group.
There was no significant difference (p = 0.13) in the incidence of target lesion revascularization
(estimates and confidence limits presented in Figure 2).
A total of 17 definite/probable stent thromboses occurred in the hybrid group during the 24-months
follow-up: In six cases, they affected both (at least) a DES and a BVS in the same patient; in four cases,
they only affected a BVS, and in one case only one DES.
Figure 3A,B show the two-years incidence, as well as estimates and confidence limits for the
incidence of stent and BVS thrombosis in both the hybrid and BVS-only group. Before testing for
differences, effects of the device type and hybrid treatment had to be separated and adjusted for
possible interactions. Thereafter, with regard to treatment strategy, only a trend towards a higher
incidence of BVS thrombosis remained in the BVS-only group (p = 0.07). With regards to the device
type, BVS and stent thrombosis rates did not differ significantly, neither within the hybrid group
(p = 0.22), between hybrid and BVS-only group (p = 0.31), nor pooled over all treatments (p = 0.07).
In the multivariable analysis, only the implantation in bifurcation lesions emerged as an
independent predictor of device thrombosis (Table 5). In separate analyses neither acute coronary
syndrome at index nor the implantatation technique used modified this association (p = 0.241 and
p = 0.637, respectively).
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Table 4. Clinical Outcomes.
Total (n = 3144) Hybrid Stenting(n = 435)
BVS Only
(n = 2709) p Value OR (95%-CI)
Periprocedural complications
Death 0% (0/3143) 0% (0/435) 0% (0/2708) n.d. -
MI 0.3% (10/3143) 0.9% (4/435) 0.2% (6/2708) <0.05 4.18(1.17–14.87)
CABG - emergency operation 0% (0/3143) 0% (0/435) 0% (0/2708) n.d. -
Coronary thrombosis 0.4% (12/3143) 0.9% (4/435) 0.3% (8/2708) 0.05 3.13(0.94–10.45)
Coronary perforation 0.5% (16/3140) 1.6% (7/435) 0.3% (9/2705) <0.001 4.9 (1.82–13.22)
30-days follow-up
All-cause mortality 0.51% (16/3144) 1.15% (5/435) 0.41% (11/2709) <0.05 2.85 (0.99–8.25)
Cardiovascular mortality 0.32% (10/3144) 0.92% (4/435) 0.22% (6/2709) < 0.05 4.18(1.18–14.88)
Scaffold thrombosis Definite 0.86% (27/3144) 1.15% (5/435) 0.81% (22/2709) 0.48 1.42 (0.53–3.77)
- Probable 0.35% (11/3144) 0.69% (3/435) 0.3% (8/2709) 0.20 2.34 (0.62–8.87)
Stent thrombosis Definite 0.23% (1/435) 0.23% (1/435) - -
- Probable 0.69% (3/435) 0.69% (3/435) - -
Any myocardial infarction 1.43% (45/3144) 1.84% (8/435) 1.37% (37/2709) 0.44 1.35 (0.63–2.93)
Target vessel related MI 1.18% (37/3144) 1.61% (7/435) 1.11% (30/2709) 0.37 1.46 (0.64–3.35)
Target lesion revascularization 1.08% (34/3144) 1.38% (6/435) 1.03% (28/2709) 0.52 1.34 (0.55–3.25)
Target lesion failure 1.49% (47/3144) 2.76% (12/435) 1.29% (35/2709) <0.05 2.17 (1.12–4.21)
Target vessel failure 1.72% (54/3144) 2.99% (13/435) 1.51% (41/2709) <0.05 2 (1.07–3.77)
24-months follow-up
Follow-up available 98.4% (3094/3144) 97.2% (423/435) 98.6% (2671/2709)
All-cause mortality 3.06% (96/3135) 4.37% (19/435) 2.85% (77/2700) 0.09 1.56 (0.93–2.6)
Cardiovascular mortality 0.96% (30/3135) 1.84% (8/435) 0.81% (22/2700) <0.05 2.28 (1.01–5.16)
Scaffold thrombosis Definite 2% (54/2694) 1.33% (5/375) 2.11% (49/2319) 0.32 0.63 (0.25–1.58)
- Probable 0.78% (21/2688) 1.33% (5/377) 0.69% (16/2311) 0.19 1.93 (0.7–5.29)
Stent thrombosis Definite 0.53% (2/374) 0.53% (2/374) - -
- Probable 1.33% (5/377) 1.33% (5/377) - -
Any myocardial infarction 5.07% (137/2703) 5.31% (20/377) 5.03% (117/2326) 0.82 1.06 (0.65–1.72)
Target vessel related MI 3.37% (91/2700) 3.19% (12/376) 3.4% (79/2324) 0.84 0.94 (0.51–1.74)
Target lesion revascularization 6% (162/2698) 7.71% (29/376) 5.73% (133/2322) 0.13 1.38 (0.91–2.09)
Target lesion failure 7.19% (195/2711) 10.24% (39/381) 6.7% (156/2330) <0.05 1.59 (1.1–2.3)
Target vessel failure 10.21% (277/2714) 14.7% (56/381) 9.47% (221/2333) <0.01 1.65 (1.2–2.26)
Any PCI 18.52% (505/2727) 23.02% (87/378) 17.79% (418/2349) <0.05 1.38 (1.06–1.79)
Values are mean ± SD or % (absolute number/number of available records); BRS = bioresorbable vascular scaffold;
CI = confidence interval; PCI = percutaneous coronary intervention; OR = Odds ratio.
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Table 5. Multivariate analysis of the predictors of definite/probable device thrombosis.
Analysis of Maximum Likelihood Estimates
Parameter Parameter Estimate Standard Error Chi-Square Pr > ChiSq Hazard Ratio
Device type 0.44883 0.36030 1.5518 0.2129 1.566
Total stent length 0.21102 0.16178 1.7015 0.1921 1.235
Lesion type B2/C −0.32342 0.26101 1.5354 0.2153 0.724
Implantation after Jan. 2015 −0.33539 0.23905 1.9683 0.1606 0.715
Bifurcation 1.04114 0.48421 4.6233 0.0315 2.832
4. Discussion
The GABI-R is a large international registry on the use of BVS. In the present analysis, we investigate
the characteristics and outcomes of patients who received hybrid stenting (i.e., at least one BVS and at
least one metallic stent). The major findings of the current analysis include: (i) Patients treated with
hybrid stent/scaffold therapy had a more complex presentation and worse outcomes than those treated
with BVS alone; (ii) During a two-years follow-up, the incidence of adverse events at the level of the
lesions treated with BVS was not worse than that of the lesions treated with metallic stents.
The concept of a vascular scaffold that provides temporary mechanical support and is resorbed
during follow-up to avoid a permanent unnecessary foreign body remains an attractive concept for
percutaneous coronary intervention. Although initial randomized trials reported non-inferiority as
compared to metallic drug-eluting stents [17,18], with signals that these devices might also be used in
more complex lesion [19–22], more recent trials have consistently demonstrated a higher incidence of
adverse events both early and late after implantation [3,4,23]. Mechanistic evidence shows that these
increased rates might depend on the technique used at the time of implantation, inadequate selection
of lesions, and, importantly, on the mechanical limitations of the devices, including increased strut
thickness, reduced expansion limits, reduced radial resistance [6,8]. Further, particular settings, such
as chronic total occlusions, acute coronary syndromes, treatment of ostial lesions and a lack of care at
the time of implantation have all been associated with increased events, including thrombosis and
restenosis [3,24–28]. Based on these notions, the general recommendation is that patients who have
been treated with BVS should prolong their dual antiplatelet therapy until complete resorption of the
device. This recommendation is likely to be particularly important in patients treated for complex
lesions, such as those presented here. Knowledge of these limitations lead to the hypothesis that,
by avoiding implantation in the presence of adverse lesion characteristics (e.g., long lesions with
proximal or distal reference vessel diameters unsuitable for BVSs, very calcific or bifurcation lesions)
may represent an adequate compromise between the benefit of the BVS and the risk of adverse events.
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Interestingly, this setting also allows within-patients comparison of the outcomes, i.e., removes the
confounding influence of differences in patient-related risk factors among groups.
Beyond any consideration on the safety of the devices implanted, it might be hypothesized that
the use of BVS might be more advantageous in long and proximal segments, which might thereafter
regain the possibility to adjust their diameter in response to biochemical and physical stimuli. Calcific
lesions, in contrast, might have theoretically less potential for regeneration. Thrombotic lesions might
also represent a setting for BVS, allowing ”plaque stabilization“ as previously reported [29]. The use
of BVS in CTO lesions has also been reported, but no data are available regarding the capacity of
these lesions to regenerate [30]. In the present database, lesions treated with BVS-only were indeed
longer and more frequently of type C (thrombotic). There was a trend towards less calcific lesions
being treated with BVS-only, but this difference remains speculative. Finally, in theory there is also a
rationale for the use of BVS in ostial or bifurcation lesions to limit (in time) the risks associated with
malapposed struts, but the evidence on their (lack of) safety in these settings clearly discouraged their
use [31]. Based on the instructions for use, in the present database, bifurcation lesions were almost
exclusively treated with metallic stents.
Reports on the short-term outcomes of this so-called hybrid stenting strategy (the use of both
metallic stents and BVS in the same patient or lesion) have been previously published [32–35].
Collectively, these studies reported that the use of a hybrid approach might be an acceptable compromise
to overcome the limitations of BVS. In the present study, we report data from a larger database with
longer follow-up. In our study, the incidence of events was similar between BVS and metallic
stents, while treatment of complex patients and lesions (particularly bifurcation lesions) remained
an independent predictor of events. These findings confirm the hypothesis that a hybrid approach,
in which more complex settings are treated with DES, might be a feasible option, although its rationale
needs to be validated. While polymeric devices of the first generation (Absorb, Abbott vascular) have
been removed from the market following the evidence of increased adverse events, the present results
might also apply to other similar devices for which data from large databases are not available. Further,
they provide a perspective for novel devices of this type.
5. Limitations
The GABI-R was a prospective registry designed to provide information on the real-life use of BVS
and is therefore affected by the limitations of this type of study design. Centralized data monitoring,
quality assessment, and follow-up were however performed to limit these issues. With regards to the
present analysis, hybrid treatment of lesions complicates the adjudications of the events to one or the
other device type. For this reason, the comparison of the incidence of device thrombosis was limited
to lesions treated with only one type of device. Despite the size of the database, conclusions on very
rare subsets (e.g., bifurcation lesions treated with hybrid strategy) were not possible. As well, data on
the antiplatelet regimen at the time of the event are missing. The present data should not be directly
extrapolated to second-generation BVS. However, they provide an insight that a prudent strategy of
hybrid stenting might allow combining the benefit of bioresorbable devices with the safety of standard
metallic stents also in more complex settings. The impact of a correct implantation technique has been
demonstrated in a number of papers, including those from our group [8,18,24,25,27,28]. Unfortunately,
the absence of a central quantitative coronary analysis in the present database does not allow clear
conclusions to this regard. Finally, the comparison of the outcomes within hybrid patients removes
patient-related confounders but not lesion-related confounders, which would be better addressed in
trials with a randomization at lesion level.
6. Conclusions
We report on the outcome of patients undergoing BVS and DES implantation, a particularly
complex subset among patients treated with BVS. In this database, which is one of the largest ones
worldwide on the use of BVS, the type of device implanted did not influence patients´ outcomes.
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Hybrid stenting is a negotiation between the concept of “full vascular regeneration” and the mechanical
limitations of these novel devices. Whether the use of metallic stents, although limited as compared to
a full-metal strategy, compromises the benefits of BVS remains however to be discussed. Whether the
use of a hybrid strategy with newer (and safer) scaffolds will present any advantage as compared to a
full-DES strategy, will need to be studied in the future.
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